Retatrutide
Triple agonist (GIP/GLP-1/glucagon) for next-generation metabolic and weight research.
12 mg/week maintenance
Key Benefits
simultaneously targets GIP, GLP-1, and glucagon receptors for synergistic metabolic effects no single agonist can match
Phase 2 trials showed 24.2% body weight loss at 48 weeks, the highest ever recorded for an injectable agent
addresses insulin resistance, dyslipidemia, and visceral fat accumulation through three complementary mechanisms
liver fat reduced by 81.7% from baseline in subgroup analysis, making it the most potent compound for fatty liver research
Recommended Injection Sites
Optimal injection locations for Retatrutide based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
Preferred site for triple agonist peptides. Consistent SubQ absorption; large depot accommodates weekly volume.
Reliable weekly rotation site. Slightly slower Cmax but equivalent weekly AUC.
Third rotation site. Requires assistance for consistent placement.
Rotate weekly: abdomen → thigh → upper arm. Systematic rotation is critical for long-term protocols to prevent injection site reactions.
- IV administration
- Intramuscular injection
- Areas with active lipodystrophy or scar tissue
Active Signaling Pathway
Retatrutide simultaneously activates three receptor types — GIP, GLP-1, and glucagon — creating synergistic metabolic effects that no single agonist can replicate. This triple mechanism produced 24.2% weight loss in Phase 2 trials.
Recommended Stacks
Retatrutide is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Retatrutide Advanced Protocol
The most potent metabolic research stack available — triple receptor agonism with full titration support.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 15mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
Retatrutide (LY3437943) simultaneously agonizes GIP, GLP-1, and glucagon receptors via a single peptide backbone with a C20 fatty diacid modification for albumin binding and extended half-life (~6 days). The triple mechanism creates synergistic effects: GIP enhances insulin secretion and fat storage regulation, GLP-1 suppresses appetite and slows gastric emptying, and glucagon drives hepatic fat oxidation and thermogenesis.
Clinical Context
The 15mg vial is designed for the full titration protocol, covering escalation from 1 mg through 8 mg and up to 12 mg/week maintenance — with enough peptide for 12+ weeks of dosing. At this dose range, Retatrutide has demonstrated the most significant body composition changes of any peptide in its class. The 15mg vial covers months 2–5 of the protocol after tolerance is established with the 5mg starter vial.
Research Highlights
- Phase 2 NEJM 2023: 24.2% mean body weight reduction at 48 weeks — the highest ever reported for any injectable anti-obesity agent
- Liver fat reduced by 81.7% from baseline in NAFLD subgroup analysis
- Visceral adipose tissue reduced by 40%+ at maximum dose — exceeding dual agonists by a significant margin
- Phase 3 trials (TRIUMPH program) ongoing; FDA Breakthrough Therapy designation under review
Storage & Reconstitution
Dose-escalation protocol: start at 1–2 mg/week, titrate up over 12–24 weeks. Monitor for GI side effects during escalation.